Medivir 2022 Annual Report published

Rhea-AI Summary

Medivir AB (NASDAQ Stockholm: MVIR) has announced the availability of its Annual Report for 2022 on its website. The report highlights significant progress in the clinical development of fostrox, a potential first-line treatment for liver cancer, which commenced Phase 2a trials in early 2023. The recruitment rate for this trial was notably high in the latter half of 2022. Additionally, several out-licensed projects are progressing positively and are anticipated to enter clinical development in 2023. The Annual Report encompasses insights into the company's innovative drug development strategy focused on addressing unmet medical needs in cancer treatment.

Positive

• Fostrox's Phase 2a clinical trials began in early 2023, showing strong recruitment in 2022.
• Out-licensed projects are advancing positively, with potential clinical programs starting in 2023.

Negative

• None.

STOCKHOLM, April 4, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR) today announces that the Annual Report for 2022 now is available at the company's website: www.medivir.com.

Medivir's cutting edge project fostrox has the potential to become the first liver-targeted, orally administered drug to help patients with various cancers of the liver, an area of great medical need. The clinical development of fostrox has been in focus in 2022 with a high recruitment rate in the second half of the year, which enabled the phase 2a part of the study, with fostrox in combination with Lenvima®, to start at the beginning of 2023. Interest in the study remains very high.

Several of the company's out-licensed projects have developed in a very positive direction during 2022 and are moving towards an exciting future. For two of these projects, clinical development programs are likely to be initiated in 2023.

This and much more can be found in Medivir's Annual Report 2022, published today at the website;
https://www.medivir.com/investors/reports#FinancialReports2022

For additional information, please contact

Magnus Christensen, CFO
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com

Medivir in brief

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.

The following files are available for download:

https://mb.cision.com/Main/652/3746717/1965866.pdf	Annual Report 2022 (PDF)
https://mb.cision.com/Public/652/3746717/ae07d59e17436112.pdf	Press release (PDF)

View original content:https://www.prnewswire.com/news-releases/medivir-2022-annual-report-published-301789365.html

SOURCE Medivir